About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?
By
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
FEATURING
Barry Greenberg
By
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
FEATURING
Barry Greenberg
2,010 views
February 5, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Related Content
AUTOPLAY
ON
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments
Primer on Diabetes Management
Feat.
S. Inzucchi
11:37
ACC 2022 Conference Coverage
ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…
Feat.
P. Heidenreich
11:25
ACC 2023 Conference Coverage
ACC 2023: SGLT2i Use - Dos and Don'ts
Feat.
A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention
Diabetes Treatment Guidelines Finally Have Entered the 21st Century …
Feat.
R. DeFronzo
12:30
Houston Methodist Hospital
Amyloidosis Types and Pathophysiology
Feat.
B. Trachtenberg
26:01
Cardiology Fiesta 2017
Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…
Feat.
R. DeFronzo
27:14
MUSC Cardiology
Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…
Feat.
R. Mentz
17:44
Rita Jermyn
SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease
27:24
Cardiometabolic Health Congress (CMHC)
SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes
Feat.
L. Sloan
13:07
Michelle Kittleson
2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …
09:52
AHA 2022 Conference Coverage
AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…
Feat.
R. Mentz
35:16
Scripps Health
HFpEF or Amyloidosis? The Right Therapies for Right Patients
Feat.
M. Kittleson
14:19
UChicago Medicine
S-QUAD Therapy and Beyond: HFpEF in 2024
Feat.
M. Belkin
17:29
UCLA Health
Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics
Feat.
D. Vucicevic
19:30
ACC 2022 Conference Coverage
Hot Topics in Heart Failure ACC.22
Feat.
N. Ibrahim
34:18
Scripps Health
Cancer Survivorship: How To Monitor for Cardiac Disease Following Tr…
Feat.
A. Kuo
84:17
Jefferson Health
2022 Heart Failure Guidelines Review
Feat.
D. Haas
28:48
MUSC Cardiology
Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures
Feat.
S. Litwin
20:59
Mary E. Money
Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…
10:02
Emory Diabetes Education Training Academy
Insulin Treatment in Patients with Type 2 Diabetes: When to Use Comb…
Feat.
G. Umpierrez
